Recombinant Human CD200 His-tag Protein, CF

When Recombinant Human CD200 R1 Fc Chimera (Catalog # 3414-CD) is immobilized at 2 µg/mL, Recombinant Human CD200 (Catalog #10032-CD) binds with an ED50 of 0.2-1.2 μg/mL.

2 μg/lane of Recombinant Human CD200 was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing bands at 38-54 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CD200 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CD200 R1 Fc Chimera (Catalog # 3414-CD) is immobilized at 2 µg/mL (100 µL/well), Recombinant Human CD200 binds with an ED₅₀ of 0.2-1.2 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human CD200 protein
  Met1-Gly232, with a C-terminal 6-His tag
• Accession #: P41217
• N-terminal Sequence: No results obtained. Gln31 inferred from enzymatic pyroglutamate treatment revealing Val32.
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 23 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 38-54 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CD200 His-tag Protein, CF

• antigen identified by monoclonal MRC OX-2
• CD200 antigenMOX1
• CD200 molecule
• CD200
• MOX1
• MOX2
• MOX2MRC
• MRC OX-2 antigen
• MRC
• OX-2 membrane glycoprotein
• OX-2

Background

CD200, also known as OX-2, is a 45 kDa transmembrane immunoregulatory protein that belongs to the immunoglobulin superfamily (1, 2). The human CD200 cDNA encodes a 278 amino acid (aa) precursor that includes a 30 aa signal sequence, a 202 aa extracellular domain (ECD), a 27 aa transmembrane segment, and a 19 aa cytoplasmic domain. The ECD is composed of one Ig-like V-type domain and one Ig-like C2-type domain (3). A splice variant of CD200 has been described and has a truncated cytoplasmic tail. Within the ECD, human CD200 shares 76% aa sequence identity with mouse and rat CD200. CD200 is widely but not ubiquitously expressed (4). Its receptor (CD200R) is restricted primarily to mast cells, basophils, macrophages, and dendritic cells, which suggests myeloid cell regulation as the major function of CD200 (5-7). CD200 knockout mice are characterized by increased macrophage number and activation and are predisposed to autoimmune disorders (8). CD200 and CD200R associate via their respective N-terminal Ig-like domains (9). In myeloid cells, CD200R initiates inhibitory signals following receptor-ligand contact (6, 7, 10). In T cells, however, CD200 functions as a costimulatory molecule independent of the CD28 pathway (11). Several additional CD200R-like molecules have been identified in human and mouse, but their capacity to interact with CD200 is controversial (12, 13). Several viruses encode CD200 homologs which are expressed on infected cells during the lytic phase (14, 15). Like CD200 itself, viral CD200 homologs also suppress myeloid cell activity, enabling increased viral propagation (5, 14-16).

1. Gorczynski, R.M. (2005) Curr. Opin. Invest. Drugs 6:483.
2. Barclay, A.N. et al. (2002) Trends Immunol. 23:285.
3. McCaughan, G.W. et al. (1987) Immunogenetics 25:329.
4. Wright, G.J. et al. (2001) Immunology 102:173.
5. Shiratori, I. et al. (2005) J. Immunol. 175:4441.
6. Cherwinski, H.M. et al. (2005) J. Immunol. 174:1348.
7. Fallarino, F. et al. (2004) J. Immunol. 173:3748.
8. Hoek, R.M. et al. (2000) Science 290:1768.
9. Hatherley, D. and A.N. Barclay (2004) Eur. J. Immunol. 34:1688.
10. Jenmalm, M.C. et al. (2006) J. Immunol. 176:191.
11. Borriello, F. et al. (1997) J. Immunol. 158:4548.
12. Gorczynski, R. et al. (2004) J. Immunol. 172:7744.
13. Hatherley, D. et al. (2005) J. Immunol. 175:2469.
14. Foster-Cuevas, M. et al. (2004) J. Virol. 78:7667.
15. Cameron, C.M. et al. (2005) J. Virol. 79:6052.
16. Langlais, C.L. et al. (2006) J. Virol. 80:3098.

Bioinformatics

• Uniprot:
  • P41217()